Everolimus for Cancer With TSC1 or TSC2 Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02201212
Recruitment Status : Active, not recruiting
First Posted : July 28, 2014
Last Update Posted : November 5, 2018
Novartis Pharmaceuticals
Information provided by (Responsible Party):
David Kwiatkowski, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : June 2019
  Estimated Study Completion Date : January 2022